The NEDD8 pathway is a known activator of the ubiquitin-protease system, a complex that is partially responsible for the degradation of proteins involved in cell-cycle regulation and neoplastic growth. In this study, we evaluated the antitumor potential of MLN4924 (pevonedistat), a potent NEDD8 inhibitor. We hypothesized that MLN4924 treatment induces apoptosis in human melanoma cells. A375 and Mel39 BRAF V600E mutant melanoma cell lines were treated in vitro with MLN4924 alone or in combination with interferon-α (IFN-α) or vemurafenib -therapeutic agents utilized on melanoma patients. Annexin/propidium iodine flow cytometry analysis showed that treatment with MLN4924 for 72 h induced apoptosis in A375 and Mel39 melanoma cells with an IC 50 of 1200 and 143 nmol/l, respectively. Combination therapy of A375 cells with 10 4 U/ml IFN-α and 1200 nmol/l MLN4924 led to a significant increase in cell death (78.2 ± 3.7%) compared with single-agent treatment by IFN-α (17.5 ± 2.5%) or MLN4924 (50.7 ± 1.0%; P < 0.005). Treatment of A375 cells with 1 μmol/l vemurafenib had a notable effect on cell viability. However, the addition of MLN4924 to vemurafenib had an inhibitory effect on apoptosis. Results from MTS proliferation assays indicate that MLN4924 has antiproliferative effects on melanoma cells in vitro, with the addition of IFN-α further inhibiting proliferation. Pretreatment with MLN4924 led to A375 cell sensitization to vemurafenib treatment and immunoblot analysis of MLN4924-treated cells revealed cleavage of caspase-3, caspase-7, caspase-9, and poly-ADP-ribose polymerase. These results show that MLN4924 does have an efficacy in treating melanoma in vitro alone or in combination with IFN-α, and thus it may have potential use in patients with advanced melanoma. Melanoma Res 28:390-397 Copyright
Introduction
Melanoma is one of the deadliest forms of cancer, with an average 10-15% 10-year survival rate for stage 4 disease [1] . While melanoma composes about 1% of all skin cancer cases in the USA, it accounts for the vast majority of skin cancer-related deaths. Incidence rates of melanoma have been steadily increasing for the last 30 years, and in 2017 there will be an estimated 87 000 new melanoma cases, leading to an estimated 9730 deaths [2] . While traditional treatments include surgical removal of the tumor, radiation therapy, and chemotherapy, a new form of therapy in advanced cases is the use of immunebased treatments. The mechanism by which the immune system functions involves an intricate system of effector cells along with checks and balances that prevent misguided attacks by immune cells on normal healthy cells. Unfortunately, malignant cancers (including melanoma) take advantage of these mechanisms by secreting cytokines and other factors that suppress the antitumor immune response, thus allowing the tumor cells to grow and proliferate [3] . Conversely, the administration of immune stimulatory cytokines such as interferon-α (IFN-α) and interleukin-2 can boost the immune system's ability to mount an antitumor response [4] . Many new immunotherapeutic strategies focus on increasing the ability of the host lymphocytes to attack the malignant cells. Some of these therapeutics are immune checkpoint inhibitors such as neutralizing antibodies specific for inhibitory proteins on T cells. PD-1 and CTLA-4 are examples of clinically important T-cell checkpoints. While these therapeutics have shown efficacy in the treatment of metastatic melanoma, detrimental side effects can occur and resistance to therapy sometimes develops [5] . Therefore, new treatments with the ability to boost the effectiveness of immunotherapy are still needed in metastatic melanoma [6] .
Advances in our understanding of the molecular basis of melanoma growth and metastasis have also occurred in the past decade. We now know that about 50% of melanoma tumors contain a mutation in the protooncogene BRAF, which causes continuous activation of the mitogen-activated protein kinase (MAPK) signal transduction pathway and ultimately leads to increased proliferation and resistance to cell death (apoptotic) signals [7] . The BRAF inhibitor vemurafenib was approved in 2011 and showed initial success in containing disease progression. Unfortunately, resistance to vemurafenib was observed in about 50% of cases after an average of 7 months. While the mechanism is not fully understood, resistance may involve the reactivation of the MAPK pathway by alternate signaling systems [8] .
IFN-α is an immune cytokine that has been used in the treatment of melanoma, primarily as an adjuvant following surgery for advanced tumors. However, previous studies have showed that IFN treatment of patients with metastatic melanoma leads to complete or partial regression of disease in about 10-15% of cases [9] . Thus, IFN-α has the potential to reduce tumor burden and the development of strategies to enhance its actions seem justified. A recent study from our group showed that combination treatment of melanoma cells with IFN-α and the novel ubiquitin-protease system (UPS) inhibitor ixazomib (MLN2238) led to enhanced levels of apoptosis [10] . A previous study performed by our group showed that IFN-α can act synergistically with the proteasome inhibitor bortezomib through enhancement of apoptosis by the Fas-FADD pathway. Notably, the combination treatment of IFN-α and bortezomib exhibited synergistic antitumor activity in multiple murine models of melanoma [11] .
Our group has studied the pathways in melanoma that lead to degradation of proteins that are important for melanoma survival. Inhibition of these pathways could lead to reduced tumor cell viability. The NEDD8 protein (81 amino acids in length) is the sole activator of the NEDD8 pathway; a complex mechanism that leads to the targeted degradation of multiple proteins through utilization of the UPS [12] . The NEDD8 pathway is initiated upon conjugation of NEDD8 protein to the NEDD8 activating enzymes (NAEs). At this point, a cascade of trans-neddylation reactions occurs, transferring NEDD8 from the NAE-NEDD8 complex to one of the multiple possible E2 complexes, and subsequently transferring it to a family of E3 ubiquitin ligases that are otherwise known as cullin-RING ligases (CRLs). A neddylated CRL can then conjugate a chain of ubiquitin molecules to a substrate, thereby targeting it for proteasomal degradation. In cancer cells, the proteasomemediated degradation of proteins is skewed toward species that enhance cell growth, survival, and proliferation [12] . Studies have shown that CRLs are responsible for ubiquinating an estimated 20% of proteins targeted for degradation through the UPS [13] . If neddylation targets a protein in a pathway that is important for survival of a malignant cell (e.g. antiapoptotic mechanisms) then the NEDD8 pathway could be seen as playing an important role in maintaining cell viability and growth in cancer.
The novel NAE inhibitor MLN4924 (pevonedistat) works by inhibition of the NEDD8 pathway. It inhibits the formation of the NAE-NEDD8 complex, thereby preventing the cascade of reactions that leads to the degradation of oncogenic proteins by the recruitment of the UPS. A study in urothelial carcinoma found that MLN4924 was able to suppress cell proliferation and migration [14] . Several ongoing studies have found MLN4924 to have an efficacy as a therapeutic agent in advanced cancer, but the effects of this drug on patients with malignant melanoma remain to be seen. We hypothesize that treatment of melanoma cells with MLN4924 will lead to the degradation of antiapoptotic proteins and the persistence of apoptotic stimuli within the cell, ultimately leading to cell death. We also hypothesize that MLN4924 will work synergistically with other melanoma therapeutics, such as IFN-α and vemurafenib, to further decrease cell viability.
Materials and methods

Materials
The A375 human melanoma cell line was purchased from the American Type Culture Collection (Manassas, Virginia, USA). The A375 vemurafenib-resistant cell line was created in Dr. Carson's laboratory over a period of time by exposing wild-type A375 to increasing doses of vemurafenib. The human metastatic melanoma cell line Mel39 was a gift from Soldano Ferrone (Harvard Medical School, Boston, Massachusetts, USA) and cultured in DMEM media supplemented 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin. Melanoma cell line M308 was kindly provided by Dr. Antoni Ribas (University of California, Los Angeles, California, USA) and was maintained in RPMI-1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/ streptomycin. MLN4924 (Velcade, PS-341) was obtained from Millennium Pharmaceuticals Inc. (Cambridge, Massachusetts, USA) and recombinant human IFN-α was obtained from Schering-Plough Inc. (Kenilworth, New Jersey, USA). Vemurafenib was obtained from Selleckchem (Boston, Massachusetts, USA).
Annexin V/propidium iodine staining
Human melanoma cell lines A375 and Mel39 were plated in a six-well plate at a concentration of 200 000 cells/well and treated with vehicle or MLN4924 for various amounts of time. Cells were harvested and apoptosisinduced phosphatidylserine (PS) exposure and cell membrane integrity were measured in tumor cells by flow cytometric analysis using APC-Annexin V and PE-propidium iodide (PI; BD Pharmingen, San Jose, California, USA), as previously described [15] . Each analysis was performed using 10 000-20 000 events and provides the percentage of the cell population that is viable or apoptotic [15] . The externalization of PS residues on the cell membrane occurs first during apoptosis. Annexin V has a high affinity for PS and monitors it Assessment of pevonedistat in melanoma Olaverria Salavaggione et al. 391
once PS transfers from the inner membrane to the outer membrane. PI is not able to penetrate viable cell membranes. Once the integrity of the cell membrane begins to degrade during apoptosis, PI can then penetrate the cell. The combination of these two agents together provides a useful assay to determine whether a cell population is viable, apoptotic, or necrotic [15] .
Immunoblot analysis
Immunoblots were prepared to probe with antibodies specific for caspase-3, cleaved caspase-3, caspase-7, cleaved caspase-7, caspase-9, poly(ADP-ribose) polymerase (PARP; Cell Signaling Technology, Danvers, Massachusetts, USA), or β-actin (Sigma, St. Louis, Missouri, USA). Following incubation with the appropriate horseradish peroxidase-conjugated secondary antibody, immune complexes were detected using an enhanced chemiluminescence detection kit (Thermo Scientific, Waltham, Massachusetts, USA).
Proliferation assays
The proliferation of melanoma cells was measured as absorbance at 490 nm using the Cell Titer 96 Aqueous One Solution Cell Proliferation MTS Assay (Promega, Madison, Wisconsin, USA). All assays were performed in triplicate. Cells were also stained with trypan blue (Life Technologies, Carlsbad, California, USA) and live/dead cell counting was used to confirm proliferation assay results.
Statistical analysis
Statistical significance of differences between groups was analyzed by analysis of variance and Student's t-test, and P values of 0.05 or less were considered to be statistically significant. P values were adjusted for multiple comparisons using the Holm-Bonferroni method.
Results
Treatment of BRAF (V600E) mutant human melanoma cell lines with MLN4924 leads to apoptotic cell death
The potential of MLN4924 to induce apoptosis was explored in the BRAF V600E mutant cell lines A375 and Mel39. Cell death was measured by Annexin V/PI staining over a time period of 72 h. As only sparse data were available before the start of this project, it was necessary to perform a titration over a wide range of concentrations to determine the IC 50 of MLN4924 for each cell line. A375 cells underwent titration treatment, starting with an untreated (negative) control and proceeding with increasing concentrations of MLN4924 from 25 to 3200 nmol/l (Fig. 1a) . Following the titration, A375 cells underwent another treatment at the calculated IC 50 concentration of 1200 nmol/l, yielding 54.1% cell death compared with untreated cells exhibiting 9.58% cell death (Fig. 1b) . Mel39 cells also underwent a titration with MLN4924 concentrations ranging from 50 to 400 nmol/l (Fig. 1c) . The calculated IC 50 concentration of MLN4924 in Mel39 was found to be 143 nmol/l. Treatment of Mel39 cells at near IC 50 concentration of 150 nmol/l yielded 52.2% cell death compared with 14.9% cell death of control untreated cells (Fig. 1d) .
Combination treatment of A375 BRAF (V600E) mutant human melanoma cell line with MLN4924 and IFN-α enhances apoptosis
To assess the capability of MLN4924 to act synergistically with other therapeutics, A375 cells were treated for 72 h with varying concentrations of MLN4924 (0, 100, 1200, or 2000 nmol/l), IFN-α (10 4 U/ml), vemurafenib (1 μmol/l), or with MLN4924 in combination with IFN-α or the Food and Drug Administration-approved BRAF inhibitor vemurafenib (Fig. 2) . All agents were added to cultures simultaneously and apoptosis levels were measured by Annexin V/PI flow cytometric staining. No treatment and single-agent treatments with IFN-α (10 4 U/ml) and vemurafenib (1 μmol/l) induced lower levels of apoptosis than MN4924 at its IC 50 concentration (1200 nmol/l, Fig. 2a ). The combination of MLN4924 with IFN-α led to an additive level of apoptosis (78.2 3.7%) in A375 cells compared with MLN4924 treatment alone (50.7 1.0%, Fig. 2b , P < 0.005). However, the combination of MLN4924 and vemurafenib did not enhance apoptosis in A375 cells, as apoptosis levels were lower with the combination of vemurafenib and MLN4924 compared with MLN4924 alone treatment at higher doses (1200 and 2000 nmol/l, Fig. 2b) .
Pretreatment of the A375 BRAF (V600E) mutant human melanoma cell line with MLN4924 led to sensitization to vemurafenib treatment It was previously shown that combination treatment of MLN4924 and vemurafenib in A375 cells led to lower levels of apoptosis compared with single-agent MLN4924 treatment. However, a recent publication by Wand et al. [16] has shown that significant levels of NEDD8 inhibition was present within 6-24 h after initial treatment with MLN4924. We therefore explored the potential of MLN4924 to serve as a sensitizer of A375 BRAF (V600E) mutant melanoma cells to vemurafenib. Cells were treated with 1200 nmol/l MLN4924 for either the first 24 h or the full 72 h of culture. Vemurafenib treatment (5 μmol/l) was initiated at the 24-h mark for a total treatment of 48 h. For some of the treatments, the media containing MLN4924 was removed and replaced after the first 24 h to prevent the mixing of MLN4924 with vemurafenib (as we previously observed an inhibitory effect) (R indicates that the media was removed and replaced at the 24-h mark before the addition of vemurafenib and NR indicates that the media was not removed and replaced). Cell death levels were measured with Annexin/PI flow cytometry. Comparison of cell death percentages between all groups shows that the combination 'R' treatment yielded the highest cell death percentage (63.4 2.3%) (Fig. 3) . This finding was significant (P < 0.05) and indicates that pretreatment of A375 BRAF mutant cells with MLN4924 could lead to moderate sensitization to vemurafenib treatment.
MLN4924 treatment alone and in combination with IFN-α or vemurafenib
Cell proliferation was assessed using the MTS assay by measuring absorbance to quantify the antiproliferative potential of MLN4924. A cell proliferation titration curve was created by treating A375 BRAF (V600E) mutant cells with MLN4924 concentrations of 0, 100, 600, 1200, and 2000 nmol/l (Fig. 4a) . Results indicated a decrease in cell proliferation with increasing concentration of MLN4924 treatment with an IC 50 of 408 nmol/l. Combination treatments with 1200 nmol/l MLN4924 and IFN-α (10 4 U/ml) or MLN4924 with 1 μmol/l vemurafenib on A375 melanoma cells were also carried out (Fig. 4b) . Similar experiments were performed with the Mel39 BRAF mutant melanoma tumor cell line ( Fig. 4c and d) . The IC 50 of MLN4924 in Mel39 cells was 142 nmol/l. Proliferation for both A375 and Mel39 cells was greatly inhibited by MLN4924 treatment, with Mel39 cells being more sensitive to the treatment compared with A375. With regard to the combination treatments, both the A375 and Mel39 cells exhibited decreased proliferation when MLN4924 was combined with IFN-α; yet, there was no such effect when combined with vemurafenib. Overall, MLN4924 showed efficacy in inhibiting melanoma tumor cell proliferation and this effect was enhanced with the addition of IFN-α.
Treatment of A375 Vem and M308 vemurafenib-resistant human melanoma tumor cells with MLN4924 led to apoptosis
A375 vemurafenib-resistant (A375 Vem) cells were created in an in-vitro setting from A375 BRAF (V600E) mutant human melanoma cells by a constant exposure to vemurafenib. M308 vemurafenib-resistant cells were isolated from a tumor of a patient who had innate resistance to vemurafenib treatment. Cells were treated with various concentrations of MLN4924 (0, 100, 1200, and 2000 nmol/l) and incubated for 72 h. Apoptosis levels were measured by Annexin V/PI flow cytometric staining. Following a comparison of the apoptotic cell percentages of wild-type A375, A375 Vem, and M308 vemurafenib-resistant melanoma tumor cells, a significant increase in susceptibility to MLN4924 was seen in the A375 Vem cell line where vemurafenib resistance was induced in vitro. However, no such effect was observed when vemurafenib resistance was innate in vivo as in the M308 cell line (Fig. 5) . The mechanism for the Pretreatment of the A375 melanoma cell line with MLN4924 sensitizes cells to vemurafenib treatment. The A375 cell line was treated with 1200 nmol/l MLN4924 for either an initial 24 h or the entire 72 h of culture. Vemurafenib treatment (5 μmol/l) was initiated at the 24-h mark for a total treatment of 48 h. For some of the treatments, media containing MLN4924 was removed and replaced after the first 24 h to prevent the mixing of MLN4924 with vemurafenib (R). NR indicates that vemurafenib was added directly to MLN4924-contained culture media. Apoptosis was assessed by Annexin V/PI flow cytometry. *P < 0.05. acquisition of vemurafenib resistance is still unknown; although, studies suggest it may be because of the reactivation of the MAPK or the PI3K/AKT pathways [15] . These findings ultimately do not allow us to definitively conclude whether vemurafenib resistance leads to susceptibility to MLN4924 treatment; yet, it does indicate that MLN4924 may have efficacy in treating vemurafenibresistant melanoma tumor cells.
Immunoblot analysis indicates possible downstream mechanisms for MLN4924 apoptosis induction
Caspases are a family of protease enzymes that are involved in the downstream execution of apoptosis. Treatment of A375 BRAF (V600E) mutant human melanoma cells with MLN4924 for 72 h enhanced the cleavage of caspase-3 but not caspase-7, caspase-9, or PARP (Fig. 6 ).
Discussion
MLN4924 (pevonedistat) is a novel NAE inhibitor that ultimately leads to the inhibition of the UPS, which is responsible for the targeted degradation of proteins in cancer and normal cells [14] . In this study, we evaluated the efficacy of MLN4924 as a potential therapeutic agent in melanoma tumor cell lines. We hypothesized that MLN4924 would stimulate apoptosis in human melanoma cells, and that it would work synergistically when utilized in combination with the immune stimulant IFN-α or the BRAF inhibitor vemurafenib. Our results show that MLN4924 does induce significant levels of apoptosis and reduced proliferation in BRAF mutant A375 and Mel39 melanoma tumor cell lines. In addition, MLN4924 does show some potential for use in the treatment of melanoma tumor cells that have acquired to resistance to vemurafenib. Combination therapy with MLN4924 and IFN-α resulted in an increase in apoptosis levels for A375 BRAF mutant cell line. This effect was also observed in the ability of combination treatment to reduce tumor cell proliferation in both BRAF mutant A375 and Mel39 melanoma cell lines. In contrast, an inhibitory effect was observed when utilizing combination therapy of vemurafenib with increasing doses of MLN4924 in A375 BRAF mutant melanoma cells for both apoptosis levels and tumor cell proliferation rates. Nevertheless, MLN4924 showed an ability to act as a sensitizing agent to vemurafenib treatment in A375 cells when MLN4924 was removed from the cells before treatment with vemurafenib.
Our immunoblot analysis shows that MLN4924-induced apoptosis was associated with the cleavage of caspase-3 but not caspase-7, caspase-9, or cleavage of PARP. These results, apart from caspase-3, contradict our original predictions, as our untreated sample should have expressed the lowest amount of cleavage. However, immunoblots from other publications show the results we expected for caspase-3, caspase-7, caspase-9, and PARP [17, 18] . The difference between our assay and these groups is that they treated T cells for 48 h, whereas in the present study cells were treated for 72 h. This difference may explain the high levels of cleavage observed in our untreated sample at the 72-h mark as the untreated A375 cells are close to being confluent at this time point. Nevertheless, when comparing the 600 and 1200 nmol/l MLN4924 dosages, we did observe an increase in the cleavage of all the caspases and PARP with increasing MLN4924 concentration.
Caspase-3 and caspase-7 are known as 'executioner caspases,' meaning that they are directly responsible for inducing apoptosis. Caspase-9, however, is known as an intrinsic activator-caspase that is responsible for the activation of executioner caspases [19] . One group has presented a model mechanism for the activation of caspase-9 that begins with the inhibition of the NEDD8 pathway due to MLN4924, leading to the inhibition of the UPS that prevents the degradation of proapoptotic p21, p27, Noxa, and Bik factors [17] . As MLN4924 treatment stimulates the activation of caspase-9, there is a possibility that MLN4924 can induce apoptosis through an intrinsic (intracellular) pathway. With regard to PARP, studies performed by other groups have verified cleavage of PARP to be a direct downstream result of the activation of caspase-3 and caspase-7 [20] .
While our immunoblot results indicate an intrinsic mechanism by which apoptosis is induced, another study performed in human cervical carcinoma cells revealed that apoptosis was induced by activation of caspase-8 as well [18] . This is interesting as caspase-8 is activated by an extrinsic pathway, meaning an extracellular ligand binds to a death receptor outside of the cell membrane leading to cleavage of caspase-8, which then cleaves executioner caspase-3, caspase-6, and caspase-7 thereby inducing apoptosis [19] .
One study found that MLN4924 treatment in lymphoma cells led to the upregulation of p27 (cyclin-dependent kinase inhibitor) and p21 (tumor suppressor protein), both of which play roles in inhibiting cell-cycle progression [17] . This may explain the reduction in proliferation observed in the A375 and Mel39 BRAF mutant melanoma cells following treatment.
MLN4924 is a novel therapeutic agent and a phase I clinical trial carried out in patients with metastatic melanoma has shown that MLN4924 led to a partial response in one patient and stable disease in 15 others (four lasting ≥ 6.5 months). It also determined the maximum tolerated dose to be 209 mg/m 2 [21] . Another study has shown that treatment of various melanoma cell lines with MLN4924 led to reduced cell viability and proliferation with an IC 50 of less than 0.3 μmol/l [22] . Although our study has found similar results in assessing the potential of MLN4924 as a cytotoxic agent, our group is the first to find that MLN4924 can work with IFN-α to serve as a sensitizer to vemurafenib treatment. In addition, we are the first to observe that MLN4924 has efficacy in treating vemurafenib-resistant melanoma tumor cells. MLN4924 treatment induces cleavage of apoptotic proteins. A375 melanoma cells were treated for 72 h with 0, 1200, or 600 nmol/l MLN4924. Cells were lysed and protein was harvested and subjected to immunoblot analysis for total or cleaved caspase-3, caspase-7, caspase-9, or PARP. β-Actin was utilized as a loading control. PARP, poly-ADP-ribose polymerase.
MLN4924 has shown potential in targeting other forms of cancers as well. One group found MLN4924 to be highly effective against human lymphoma cells (in vitro) compared with the classical proteasome inhibitor MG132. Interestingly, immunoblots showed the inhibition of the antiapoptotic Bcl-2 and Mcl-1 protein families [17] . Another study performed in human urothelial carcinoma found MLN4924 to induce apoptosis and inhibit tumor cell proliferation in vitro. Studies in xenograph mouse models found dose-dependent cytotoxic effects, along with inhibition of proliferation, migration, and invasion effects when mice were treated with MLN4924 [23] .
MLN4924 appears to have efficacy in treating various forms of cancers both in vitro and in vivo. MLN4924 has been shown to be well-tolerated toxicity in mouse models; several clinical trials are ongoing [23] . Our group will continue to assess the potential of MLN4924 as a melanoma therapeutic.
